What does an elevated ferritin level indicate and how should it be evaluated and managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Elevated Ferritin: Evaluation and Management

Measure transferrin saturation (TS) immediately—this single test determines whether you are dealing with true iron overload or one of the far more common secondary causes of hyperferritinemia.

The vast majority (>90%) of elevated ferritin cases are not due to iron overload but rather reflect inflammation, chronic alcohol use, liver disease, malignancy, or metabolic syndrome. 1, 2, 3 Ferritin is an acute-phase reactant that rises during inflammation, infection, hepatocellular injury, and tissue necrosis independent of actual iron stores. 1, 2


Immediate Diagnostic Algorithm

Step 1: Order Fasting Transferrin Saturation

Order these tests together:

  • Fasting transferrin saturation (TS) 1, 4
  • Complete metabolic panel (ALT, AST, bilirubin, alkaline phosphatase) 1, 4
  • Inflammatory markers (CRP, ESR) 1, 4
  • Complete blood count with differential 4

Step 2: Interpret Based on Transferrin Saturation

If TS ≥ 45%: Suspect Primary Iron Overload

This pattern indicates true iron overload requiring immediate genetic evaluation. 1, 4, 2

  • Order HFE genetic testing for C282Y and H63D mutations immediately. 1, 4, 2, 5
  • C282Y homozygosity or C282Y/H63D compound heterozygosity confirms hereditary hemochromatosis. 1, 4, 2, 5
  • TS ≥ 45% provides 84% sensitivity in men and 73% sensitivity in women for detecting C282Y homozygosity. 1, 2

Risk stratification by ferritin level when TS ≥ 45%:

Ferritin Level Risk & Action Citation
< 1,000 µg/L Low risk of organ damage (94% NPV for advanced fibrosis). If C282Y homozygote, age <40, normal liver enzymes, no hepatomegaly: start therapeutic phlebotomy without liver biopsy. [1,4,2]
> 1,000 µg/L High risk: 20-45% prevalence of cirrhosis in C282Y homozygotes. Consider liver biopsy if: elevated ALT/AST, platelet count <200,000/µL, age >40, or hepatomegaly. [1,4,2]
> 10,000 µg/L Rarely simple iron overload. Urgent specialist referral to evaluate for adult-onset Still's disease, hemophagocytic lymphohistiocytosis, or macrophage activation syndrome. [1,6]

When ferritin >1,000 µg/L with elevated aminotransferases and platelet count <200,000/µL, cirrhosis is present in ~80% of C282Y homozygotes. 1, 4, 2

If TS < 45%: Iron Overload Excluded—Evaluate Secondary Causes

Iron overload is excluded with >90% certainty when TS <45%. 1, 2, 3 The elevated ferritin reflects one of these secondary causes:

Common secondary causes (account for >90% of cases): 1, 2, 3

  1. Chronic liver disease:

    • Alcoholic liver disease 1, 2, 5
    • Non-alcoholic fatty liver disease (NAFLD)/metabolic syndrome 1, 4, 2
    • Viral hepatitis (B or C) 1, 2, 5
    • Acute hepatitis 1, 2
  2. Inflammatory conditions:

    • Chronic rheumatologic diseases 1, 2
    • Inflammatory bowel disease 4, 2
    • Infections 1, 2, 6
    • Adult-onset Still's disease (ferritin often >10,000 ng/mL with glycosylated ferritin <20%) 1, 4, 6
  3. Malignancy:

    • Solid tumors 1, 2, 6
    • Lymphomas 1, 4, 6
    • Hepatocellular carcinoma 4, 2
  4. Cellular damage:

    • Muscle necrosis 1, 2
    • Hepatocellular necrosis 1, 2
    • Tissue breakdown 1, 2
  5. Other conditions:

    • Chronic kidney disease 1, 4
    • Metabolic syndrome/obesity/diabetes 1, 4, 3

Therapeutic Phlebotomy Protocol (for Confirmed Hereditary Hemochromatosis)

Initiate therapeutic phlebotomy when C282Y homozygosity is confirmed with TS ≥45% and elevated ferritin. 1, 4

Induction Phase

  • Remove 500 mL of blood weekly or biweekly as tolerated. 1, 4
  • Check hemoglobin/hematocrit before each session; allow hemoglobin to fall no more than 20% from baseline. 1, 4
  • Check ferritin after every 10-12 phlebotomies. 1, 4
  • Target ferritin: 50-100 µg/L. 1, 4

Maintenance Phase

  • Once target ferritin is achieved, perform maintenance phlebotomy every 2-4 months to keep ferritin 50-100 µg/L. 1, 4
  • Monitor ferritin every 3 months once stable. 1, 4

Critical Lifestyle Modifications

  • Avoid iron supplements entirely. 1, 4
  • Avoid vitamin C supplementation (accelerates iron mobilization and increases oxidative stress). 1, 4
  • Avoid raw shellfish (risk of Vibrio vulnificus infection in iron-overloaded patients). 1, 4

Family Screening

Screen all first-degree relatives with HFE genotype testing and phenotype assessment (ferritin and TS), regardless of symptoms. 1, 4, 2 Penetrance is higher in family members than in the general population. 1


Expected Outcomes with Early Treatment

Therapeutic phlebotomy initiated before cirrhosis or diabetes develops prevents hepatic cirrhosis, primary liver cancer, diabetes mellitus, hypogonadism, arthropathy, and cardiomyopathy. 1, 4 Survival is comparable to the general population when treatment begins early. 1 Phlebotomy does not reverse established cirrhosis but halts progression. 1, 4


Critical Pitfalls to Avoid

  • Never use ferritin alone to diagnose iron overload—ferritin is an acute-phase reactant elevated in inflammation, liver disease, malignancy, and tissue necrosis independent of iron stores. 1, 4, 2, 3
  • Never order HFE genetic testing when TS <45%—this leads to misdiagnosis and unnecessary phlebotomy. 1, 2
  • Do not overlook liver biopsy in patients with ferritin >1,000 µg/L and abnormal liver tests—histology is essential for cirrhosis assessment. 1, 4, 2
  • Do not fail to screen first-degree relatives once hereditary hemochromatosis is confirmed. 1, 4
  • Do not assume iron overload when TS <45%—in the general population, iron overload is NOT the most common cause of elevated ferritin. 1, 2, 3

When to Refer to Specialist

Refer to gastroenterology, hepatology, or hematology when: 1, 4

  • Ferritin >1,000 µg/L with elevated bilirubin
  • Ferritin >10,000 µg/L regardless of other findings
  • Confirmed TS ≥45% on repeat testing
  • Clinical evidence of cirrhosis (platelet count <200,000/µL, elevated bilirubin, hepatomegaly)
  • Confirmed C282Y homozygosity requiring therapeutic phlebotomy

Special Clinical Contexts

Non-Alcoholic Fatty Liver Disease (NAFLD)

**When TS <45% with elevated ferritin and elevated ALT, the ferritin elevation reflects hepatocellular injury and insulin resistance rather than iron overload.** 1, 4, 2 **Treat the underlying metabolic condition (weight loss, metabolic syndrome management), not the elevated ferritin.** 1, 4 NAFLD patients with elevated ferritin do not require iron overload evaluation unless TS is also elevated (>45%). 4

Chronic Kidney Disease

In CKD patients with ferritin 500-1,200 ng/mL but TS <25%, intravenous iron may still be beneficial for anemia management, especially if receiving erythropoietin therapy. 1, 4 This represents functional iron deficiency despite elevated ferritin. 1, 4 Withhold iron therapy when ferritin exceeds 1,000 ng/mL or TS exceeds 50%. 1

Adult-Onset Still's Disease

Consider adult-onset Still's disease when ferritin >10,000 ng/mL with persistent fever. 1, 4, 6 Glycosylated ferritin fraction <20% is 93% specific for AOSD when combined with 5-fold ferritin elevation. 1, 4

References

Guideline

Management of Elevated Ferritin Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hyperferritinemia Causes and Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Elevated serum ferritin - what should GPs know?

Australian family physician, 2012

Guideline

Management of Elevated Ferritin Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Iron overload disorders.

Hepatology communications, 2022

Research

Causes and significance of markedly elevated serum ferritin levels in an academic medical center.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.